Pliant Therapeutics (PLRX) Net Cash Flow (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Net Cash Flow of -$23.3 million for Q1 2026, down 212.08% year-over-year from $20.7 million in Q1 2025, and up 51.84% quarter-over-quarter from -$48.3 million in Q4 2025.
Pliant Therapeutics (PLRX) Net Cash Flow (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Net Cash Flow for 8 consecutive years, with -$23.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 212.08% year-over-year to -$23.3 million; the TTM figure through Mar 2026 stood at -$69.7 million (down 211.91% YoY), while the FY2025 annual figure was -$25.7 million, down 423.65% from the prior year.
- Net Cash Flow climbed to -$23.3 million in Q1 2026 per PLRX's latest filing, from -$48.3 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $68.8 million in Q1 2023 and bottomed at -$48.3 million in Q4 2025.
- Historically, Net Cash Flow has averaged -$1.6 million across 5 years, with a median of -$5.1 million in 2025.
- Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 30249.21% — and 2025, when it jumped 997.66%.
- Pliant Therapeutics' Net Cash Flow stood at -$10.9 million in 2022, then surged by 164.37% to $7.0 million in 2023, then plunged by 219.75% to -$8.4 million in 2024, then slumped by 472.94% to -$48.3 million in 2025, then jumped by 51.84% to -$23.3 million in 2026.
- Business Quant data shows PLRX's Net Cash Flow at -$23.3 million in Q1 2026, -$48.3 million in Q4 2025, and $6.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 225.59 Mn |
| 10 | Pliant Therapeutics | 71.52 Mn | 71.52 Mn | - | 2.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.69 Mn |
| Jun 30, 2026 | 2.69 Mn |
| Mar 31, 2026 | -23.26 Mn |
| Mar 31, 2026 | -23.26 Mn |
| Dec 31, 2025 | -48.29 Mn |
| Dec 31, 2025 | -48.29 Mn |
| Sep 30, 2025 | 6.91 Mn |
| Sep 30, 2025 | 6.91 Mn |
| Jun 30, 2025 | -5.12 Mn |
| Jun 30, 2025 | -5.12 Mn |
| Mar 31, 2025 | 20.75 Mn |
| Mar 31, 2025 | 20.75 Mn |
| Dec 31, 2024 | -8.43 Mn |
| Dec 31, 2024 | -8.43 Mn |
| Sep 30, 2024 | -770,000.00 |
| Sep 30, 2024 | -770,000.00 |
| Jun 30, 2024 | -33.91 Mn |
| Jun 30, 2024 | -33.91 Mn |
| Mar 31, 2024 | 51.06 Mn |
| Mar 31, 2024 | 51.06 Mn |